ClinicalTrials.Veeva

Menu
W

Washington Institute for Coagulation | Seattle, WA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

PF-06741086
HMB-001
Emicizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 7 total trials
Locations recently updated

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

The goal of this clinical trial is to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participan...

Enrolling
Glanzmann Thrombasthenia
Drug: HMB-001

This is a multicenter, open-label, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of emicizumab i...

Active, not recruiting
Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor
Hemophilia A
Drug: Emicizumab

This is an open-label, single-dose, multi-center, multinational trial to demonstrate the efficacy of AMT-061 and to further describe its safety profi...

Active, not recruiting
Hemophilia B
Biological: Factor IX (FIX)
Genetic: AAV5-hFIXco-Padua

A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or...

Enrolling
Hemophilia B
Hemophilia A
Diagnostic Test: Testing of hepatic AAV Vector integration

Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to...

Active, not recruiting
Hemophilia B
Hemophilia A
Drug: PF-06741086

C3731003 is a pivotal Phase 3 study to evaluate the clinical efficacy and safety of a single IV infusion of PF-07055480 / giroctocogene fitelparvovec...

Active, not recruiting
Hemophilia A
Biological: PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy

Trial sponsors

Pfizer logo
CSL Behring logo
H
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems